APA

Gumbiner B., Joh T., Liang H., Wan H., Levisetti M., Vana A. M., Shelton D. L., Forgues P., Billotte S., Pons J., Baum C. M. & Garzone P. D. (20180827). The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. : Cardiovascular therapeutics.

Chicago

Gumbiner Barry, Joh Tenshang, Liang Hong, Wan Hong, Levisetti Matteo, Vana Alicia M, Shelton David L, Forgues Philippe, Billotte Stephan, Pons Jaume, Baum Charles M and Garzone Pamela D. 20180827. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. : Cardiovascular therapeutics.

Harvard

Gumbiner B., Joh T., Liang H., Wan H., Levisetti M., Vana A. M., Shelton D. L., Forgues P., Billotte S., Pons J., Baum C. M. and Garzone P. D. (20180827). The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. : Cardiovascular therapeutics.

MLA

Gumbiner Barry, Joh Tenshang, Liang Hong, Wan Hong, Levisetti Matteo, Vana Alicia M, Shelton David L, Forgues Philippe, Billotte Stephan, Pons Jaume, Baum Charles M and Garzone Pamela D. The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. : Cardiovascular therapeutics. 20180827.